RE: Nasdaq listing8 May 2024 08:45
Exactly..
“In due course, the Company expects to re-list on a regulated investment exchange that recognises the true underlying value of the business. We remain a British company, and we are proud to be part of the UK life sciences sector and believe in its strength and depth. We also note a perceived rising tide of informed market sentiment that appears to suggest quoted companies may realise a better reflection of their intrinsic valuations by moving their listing to North America. The US, specifically NASDAQ, provides an attractive option with its deep pool of life science capital markets.”